These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15865259)

  • 1. Effects of combined treatment with sildenafil and itraconazole on the cardiovascular system in telemetered conscious dogs.
    Kim EJ; Seo JW; Hwang JY; Han SS
    Drug Chem Toxicol; 2005; 28(2):177-86. PubMed ID: 15865259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall cardiovascular profile of sildenafil citrate.
    Zusman RM; Morales A; Glasser DB; Osterloh IH
    Am J Cardiol; 1999 Mar; 83(5A):35C-44C. PubMed ID: 10078541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac electrophysiologic and hemodynamic effects of sildenafil, a PDE5 inhibitor, in anesthetized dogs.
    Sugiyama A; Satoh Y; Shiina H; Takahara A; Yoneyama M; Hashimoto K
    J Cardiovasc Pharmacol; 2001 Dec; 38(6):940-6. PubMed ID: 11707698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular effects of sildenafil citrate and recommendations for its use.
    Kloner RA; Zusman RM
    Am J Cardiol; 1999 Sep; 84(5B):11N-17N. PubMed ID: 10503571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers.
    Kimura M; Higashi Y; Hara K; Noma K; Sasaki S; Nakagawa K; Goto C; Oshima T; Yoshizumi M; Chayama K
    Hypertension; 2003 May; 41(5):1106-10. PubMed ID: 12695418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of oxatomide, an antiallergic agent, on QT interval in dogs.
    Iwamoto K; Ikeda J; Nito M; Kosaka N; Ichikawa S; Ohmori K; Sakai K
    Arzneimittelforschung; 2001; 51(12):971-6. PubMed ID: 11799844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil.
    Pomara G; Morelli G; Pomara S; Taddei S; Ghiadoni L; Dinelli N; Travaglini F; Dicuio M; Mondaini N; Salvetti A; Selli C
    J Androl; 2004; 25(4):625-9. PubMed ID: 15223851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of sildenafil citrate (viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure.
    Piccirillo G; Nocco M; Lionetti M; Moisè A; Naso C; Marigliano V; Cacciafesta M
    Am Heart J; 2002 Apr; 143(4):703-10. PubMed ID: 11923809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease.
    Conti CR; Pepine CJ; Sweeney M
    Am J Cardiol; 1999 Mar; 83(5A):29C-34C. PubMed ID: 10078540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current.
    Butrous G; Siegel RL
    Circulation; 2001 Jun; 103(23):E119-20; author reply E119-20. PubMed ID: 11401951
    [No Abstract]   [Full Text] [Related]  

  • 11. Sildenafil in patients with cardiovascular disease.
    Brindis RG; Kloner RA
    Am J Cardiol; 2003 Nov; 92(9A):26M-36M. PubMed ID: 14609621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist.
    Webb DJ; Freestone S; Allen MJ; Muirhead GJ
    Am J Cardiol; 1999 Mar; 83(5A):21C-28C. PubMed ID: 10078539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological activities of novel beta-carbolines as PDE5 inhibitors.
    Sui Z; Guan J; Macielag MJ; Jiang W; Qiu Y; Kraft P; Bhattacharjee S; John TM; Craig E; Haynes-Johnson D; Clancy J
    Bioorg Med Chem Lett; 2003 Feb; 13(4):761-5. PubMed ID: 12639576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference.
    Ströberg P; Murphy A; Costigan T
    Clin Ther; 2003 Nov; 25(11):2724-37. PubMed ID: 14693300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model.
    De Young L; Yu D; Freeman D; Brock GB
    Int J Impot Res; 2003 Oct; 15(5):347-54. PubMed ID: 14562136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sildenafil citrate does not affect QT intervals and QT dispersion: an important observation for drug safety.
    Alpaslan M; Onrat E; Samli M; Dincel C
    Ann Noninvasive Electrocardiol; 2003 Jan; 8(1):14-7. PubMed ID: 12848808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sympathetic activation by sildenafil.
    Phillips BG; Kato M; Pesek CA; Winnicki M; Narkiewicz K; Davison D; Somers VK
    Circulation; 2000 Dec; 102(25):3068-73. PubMed ID: 11120696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiation of sildenafil-induced hypotension is minimal with nitrates generating a radical intermediate.
    Schwemmer M; Bassenge E; Stoeter M; Hartmann B; Hess U; Fink B
    J Cardiovasc Pharmacol; 2001 Jul; 38(1):149-55. PubMed ID: 11444498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise.
    Traverse JH; Chen YJ; Du R; Bache RJ
    Circulation; 2000 Dec; 102(24):2997-3002. PubMed ID: 11113052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.
    Chen HH; Huntley BK; Schirger JA; Cataliotti A; Burnett JC
    J Am Soc Nephrol; 2006 Oct; 17(10):2742-7. PubMed ID: 16928803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.